---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-037192"
form_type: "8-K"
ticker: "ADPT"
cik: "0001478320"
company_name: "Adaptive Biotechnologies Corp"
filed_at: "2023-08-02T23:59:59+00:00"
generated_at: "2026-06-12T12:50:44.467561+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Adaptive Biotech Q2 revenue up 12% to $48.9M; net loss narrows; MRD chief exits

## Summary
- Revenue $48.9M (+12% YoY); MRD revenue $25.9M (+22%); Immune Medicine $23.0M (+3%).
- clonoSEQ test volume +52% to 13,665 tests delivered.
- Net loss $47.8M vs $52.1M YoY; adjusted EBITDA loss $24.8M vs $33.1M.
- Full-year 2023 revenue guidance reiterated at $205-215M; operating expenses expected below 2022's $385.5M.
- Nitin Sood, Chief Commercial Officer of MRD, resigns effective Aug 15; Susan Bobulsky assumes additional responsibilities, reports to CEO.

## SEC filing metadata
- accession: 0000950170-23-037192
- form_type: 8-K
- ticker: ADPT
- cik: 0001478320
- company_name: Adaptive Biotechnologies Corp
- filed_at: 2023-08-02T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1478320/000095017023037192/0000950170-23-037192-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1478320/000095017023037192/adpt-20230728.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-037192
- JSON: https://secwatch.observer/filing/0000950170-23-037192.json
- Plain text: https://secwatch.observer/filing/0000950170-23-037192.txt

## Key facts
- Earnings Releases
  Adaptive Biotechnologies Corp reported the quarter ended June 30, 2023 results: revenue $48.9 million, net income $47.8 million. Guidance reaffirmed.
  - Period: the quarter ended June 30, 2023
  - Revenue: $48.9 million
  - Net income: $47.8 million
  - Guidance: reaffirmed
  - Result: reported results
  source text: Immune Medicine businesses and we remain committed to driving operational efficiencies across the company while supporting sustainable growth.” Recent Highlights • Revenue of $48.9 million for the second quarter 2023, representing 12% growth from $43.7 million in the second quarter 2022. • clonoSEQ test volume in the second quarter 2023 grew 52% to 13,665 tests
  evidence_url: https://www.sec.gov/Archives/edgar/data/1478320/000095017023037192/0000950170-23-037192-index.htm
- Executive change
  Nitin Sood resigned as Chief Commercial Officer of the MRD business at Adaptive Biotechnologies Corp.
  - Action: resigned
  - Role: Chief Commercial Officer of the MRD business
  source text: On July 28, 2023, the Company's Chief Commercial Officer of the MRD business, Nitin Sood, resigned to pursue a new opportunity.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1478320/000095017023037192/0000950170-23-037192-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.